Public trial registry of the CCC-Munich

Trial AMLSG 21-13

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
AMLSG 21-13
World
Full title
:

Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Versand mit GO, T: 07345-800610

World
NCT number
:
World
Responsible organization
:
3. Med 3. Med Ismaninger Str. 22 81675 München Germany
Indications
Classification Code Description
- Bloodcancer (leukemia, lymphoma)
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Positive
World
Institutional review board - vote date
:
2014-07-14
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy line
:
1
World
Therapy
:

Chemo

Participants
Function Prename Surname Organization
World Responsible contact Katharina Götze 3. Med 3. Med Ismaninger Str. 22 81675 München Germany Magnifier